Patents by Inventor Brittan L. Pasloske

Brittan L. Pasloske has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140099715
    Abstract: The present invention provides improved methods of attenuating gene expression through the phenomenon of RNA interference. The invention provides methods of synthesis of double stranded RNAs (dsRNAs) of increased potency for use as small interfering RNA (siRNA). Surprisingly and unexpectedly, siRNAs made by the methods of the invention are significantly more potent than previously available siRNAs.
    Type: Application
    Filed: August 21, 2013
    Publication date: April 10, 2014
    Applicant: Applied Biosystems, LLC
    Inventors: David Brown, Lance P. Ford, Vince Pallotta, Brittan L. Pasloske, Richard A. Jarvis
  • Patent number: 8524680
    Abstract: The present invention provides improved methods of attenuating gene expression through the phenomenon of RNA interference. The invention provides methods of synthesis of double stranded RNAs (dsRNAs) of increased potency for use as small interfering RNA (siRNA). Surprisingly and unexpectedly, siRNAs made by the methods of the invention are significantly more potent than previously available siRNAs.
    Type: Grant
    Filed: August 31, 2009
    Date of Patent: September 3, 2013
    Assignee: Applied Biosystems, LLC
    Inventors: David Brown, Lance P. Ford, Richard A. Jarvis, Vince Pallotta, Brittan L. Pasloske
  • Publication number: 20130143275
    Abstract: The invention relates to methods for the detection of a specific sequence of RNA in a cell or tissue sample. The invention also relates to methods to enzymatically manipulate the RNA in a crude cell lysate in a number of applications.
    Type: Application
    Filed: September 14, 2012
    Publication date: June 6, 2013
    Applicant: Applied Biosystems, LLC
    Inventors: Brittan L. PASLOSKE, Quoc Hoang
  • Patent number: 8426126
    Abstract: The invention relates to methods of separating polynucleotides, such as DNA, RNA and PNA, from solutions containing polynucleotides by reversibly binding the polynucleotides to a solid surface, such as a magnetic microparticle.
    Type: Grant
    Filed: September 30, 2004
    Date of Patent: April 23, 2013
    Assignee: Applied Biosystems, LLC
    Inventors: Gary J. Latham, Xingwang Fang, Richard C. Conrad, Jon A. Kemppainen, Robert A. Setterquist, Brittan L. Pasloske
  • Publication number: 20120322112
    Abstract: The invention relates to methods for the detection of a specific sequence of RNA in a cell or tissue sample. The invention also relates to methods to enzymatically manipulate the RNA in a crude cell lysate in a number of applications.
    Type: Application
    Filed: May 3, 2012
    Publication date: December 20, 2012
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Brittan L. Pasloske, Quoc Hoang
  • Publication number: 20120183962
    Abstract: The invention relates generally to the fields of making biological unit lysates or admixtures of body fluids and of RNA analysis. More specifically, it relates to direct methods for the detection of a specific sequence of RNA in a biological unit, for example a virus, cell or tissue sample, or a body fluid, for example saliva, sputum, blood plasma, etc. More generally, the invention may be used to enzymatically manipulate and protect the RNA in lysate or bodily fluids for a number of applications.
    Type: Application
    Filed: January 17, 2012
    Publication date: July 19, 2012
    Applicant: APPLIED BIOSYSTEMS, LLC
    Inventors: Brittan L. Pasloske, Xingwang Fang, Quoc Hoang
  • Publication number: 20120065105
    Abstract: Ligation-enhanced nucleic acid detection assay embodiments for detection of RNA or DNA are described. The assay embodiments rely on ligation of chimeric oligonucleotide probes to generate a template for amplification and detection. The assay embodiments are substantially independent of the fidelity of a polymerase for copying compromised nucleic acid. Very little background amplification is observed and as few as 1000 copies of target nucleic acid can be detected. Method embodiments are particularly adept for detection of RNA from compromised samples such as formalin-fixed and paraffin-embedded samples. Heavily degraded and cross-linked nucleic acids of compromised samples, in which classic quantitative real time PCR assays typically fail to adequately amplify signal, can be reliably detected and quantified.
    Type: Application
    Filed: July 26, 2011
    Publication date: March 15, 2012
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: R. Scott Kuersten, Brittan L. Pasloske
  • Patent number: 8114594
    Abstract: The invention relates generally to the fields of making biological unit lysates or admixtures of body fluids and of RNA analysis. More specifically, it relates to direct methods for the detection of a specific sequence of RNA in a biological unit, for example a virus, cell or tissue sample, or a body fluid, for example saliva, sputum, blood plasma, etc. More generally, the invention may be used to enzymatically manipulate and protect the RNA in lysate or bodily fluids for a number of applications.
    Type: Grant
    Filed: June 23, 2009
    Date of Patent: February 14, 2012
    Assignee: Applied Biosysyems, LLC
    Inventors: Brittan L. Pasloske, Xingwang Fang, Quoc Hoang
  • Publication number: 20110257375
    Abstract: Described herein is the use of antibody-based delivery agents to target and deliver nucleic acid agents into specific cell types. Herein, we describe methods used that improve the ability of conjugates that load over 3 siRNA per conjugate and target siRNA to cells expressing the appropriate cell surface antigens. We also contemplate the use of antibody, targeting peptides, small molecules, aptamers and all other factors known in the art that can specifically target tissues. In each case, these targeting moieties can be conjugated using chemical crosslinking agents to carriers enabling directed delivery of nucleic acids.
    Type: Application
    Filed: February 11, 2009
    Publication date: October 20, 2011
    Inventors: Lance P. Ford, Joe Krebs, Brittan L. Pasloske
  • Patent number: 8008010
    Abstract: Ligation-enhanced nucleic acid detection assay embodiments for detection of RNA or DNA are described. The assay embodiments rely on ligation of chimeric oligonucleotide probes to generate a template for amplification and detection. The assay embodiments are substantially independent of the fidelity of a polymerase for copying compromised nucleic acid. Very little background amplification is observed and as few as 1000 copies of target nucleic acid can be detected. Method embodiments are particularly adept for detection of RNA from compromised samples such as formalin-fixed and paraffin-embedded samples. Heavily degraded and cross-linked nucleic acids of compromised samples, in which classic quantitative real time PCR assays typically fail to adequately amplify signal, can be reliably detected and quantified.
    Type: Grant
    Filed: June 27, 2008
    Date of Patent: August 30, 2011
    Assignee: Applied Biosystems, LLC
    Inventors: R. Scott Kuersten, Brittan L. Pasloske
  • Publication number: 20100184039
    Abstract: The present invention concerns methods and compositions involving labeled, double-stranded RNA (dsRNA), including siRNA, capable of triggering RNA-mediated interference (RNAi) in a cell. Compositions of the invention include labeled dsRNA for RNAi, which may be a single strand of RNA that basepairs with itself or two separate RNA strands. In some embodiments, the label is fluorescent. The present invention further concerns methods for preparing such composition and kits for implementing such methods. Other methods of the invention include ways of using labeled dsRNA for RNAi.
    Type: Application
    Filed: September 28, 2009
    Publication date: July 22, 2010
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Lance P. Ford, Mike Byrom, Brittan L. Pasloske
  • Publication number: 20100167287
    Abstract: The invention relates generally to the fields of making biological unit lysates or admixtures of body fluids and of RNA analysis. More specifically, it relates to direct methods for the detection of a specific sequence of RNA in a biological unit, for example a virus, cell or tissue sample, or a body fluid, for example saliva, sputum, blood plasma, etc. More generally, the invention may be used to enzymatically manipulate and protect the RNA in lysate or bodily fluids for a number of applications.
    Type: Application
    Filed: June 23, 2009
    Publication date: July 1, 2010
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Brittan L. Pasloske, Xingwang Fang, Quoc Hoang
  • Publication number: 20090286304
    Abstract: The present invention concerns a compositions and method for isolating a nucleic acid from a cell-containing sample. There is disclosed a method comprising obtaining at least one cell-containing sample, which comprises a cell containing nucleic acid, obtaining at least one catabolic enzyme, obtaining at least one nuclease inhibitor, preparing an admixture of the sample, the catabolic enzyme, and the nuclease inhibitor, maintaining the admixture under conditions where the catabolic enzyme is active, and agitating the admixture, where the sample is digested to produce a nucleic acid-containing lysate of the sample.
    Type: Application
    Filed: May 11, 2009
    Publication date: November 19, 2009
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Gary Latham, Brittan L. Pasloske, Heidi Peltier
  • Patent number: 7445901
    Abstract: Methods and compositions for inhibiting and/or inactivating nucleases by employing nuclease inhibitors are provided. The nuclease inhibitors comprise anti-nuclease antibodies and non-antibody nuclease inhibitors. The anti-nuclease antibodies of the present invention may be a polyclonal or monoclonal antibodies, and may be anti-ribonuclease antibodies, anti-deoxyribonuclease antibodies, or antibodies to non-specific nucleases. A preferred embodiment comprises at least two nuclease inhibitors, and is referred to as a nuclease inhibitor cocktail. In some specific embodiments, the invention concerns methods of performing in vitro translation comprising obtaining a first nuclease inhibitor, which inhibitor is further defined as an anti-nuclease antibody, and placing the anti-nuclease antibody in an in vitro translation reaction. In many cases, the in vitro translation reaction comprises at least one nuclease, which may be a ribonuclease, a deoxyribonuclease, or a nonspecific nuclease.
    Type: Grant
    Filed: December 6, 2006
    Date of Patent: November 4, 2008
    Assignee: Applera Corporation
    Inventors: W. Antoni Kudlicki, Matthew M. Winkler, Brittan L. Pasloske
  • Patent number: 7264932
    Abstract: Methods and compositions for inhibiting and/or inactivating nucleases by using nuclease inhibitors are provided. The nuclease inhibitors comprise anti-nuclease antibodies and non-antibody nuclease inhibitors.
    Type: Grant
    Filed: February 25, 2004
    Date of Patent: September 4, 2007
    Assignee: Applera Corporation
    Inventors: Gary J. Latham, Matthew M. Winkler, Brittan L. Pasloske, W. Antoni Kudlicki
  • Patent number: 7163793
    Abstract: Methods and compositions for inhibiting and/or inactivating nucleases by employing nuclease inhibitors are provided. The nuclease inhibitors comprise anti-nuclease antibodies and non-antibody nuclease inhibitors. The anti-nuclease antibodies of the present invention may be a polyclonal or monoclonal antibodies, and may be anti-ribonuclease antibodies, anti-deoxyribonuclease antibodies, or antibodies to non-specific nucleases. A preferred embodiment comprises at least two nuclease inhibitors, and is referred to as a nuclease inhibitor cocktail. In some specific embodiments, the invention concerns methods of performing in vitro translation comprising obtaining a first nuclease inhibitor, which inhibitor is further defined as an anti-nuclease antibody, and placing the anti-nuclease antibody in an in vitro translation reaction. In many cases, the in vitro translation reaction comprises at least one nuclease, which may be a ribonuclease, a deoxyribonuclease, or a nonspecific nuclease.
    Type: Grant
    Filed: September 30, 2003
    Date of Patent: January 16, 2007
    Assignee: Ambion, Inc.
    Inventors: W. Antoni Kudlicki, Matthew M. Winkler, Brittan L. Pasloske
  • Patent number: 7033749
    Abstract: The present invention relates to nuclease resistant nucleic acids in general and ribonuclease resistant RNAs in particular. Methods of making and using such nucleic acids are disclosed.
    Type: Grant
    Filed: April 10, 2002
    Date of Patent: April 25, 2006
    Assignees: Ambion, Inc., Cenetron Diagnostics LLC
    Inventors: Brittan L. Pasloske, Dwight B. DuBois, David M. Brown, Matthew M. Winkler
  • Publication number: 20040248094
    Abstract: The present invention concerns methods and compositions involving labeled, double-stranded RNA (dsRNA), including siRNA, capable of triggering RNA-mediated interference (RNAi) in a cell. Compositions of the invention include labeled dsRNA for RNAi, which may be a single strand of RNA that basepairs with itself or two separate RNA strands. In some embodiments, the label is fluorescent. The present invention further concerns methods for preparing such composition and kits for implementing such methods. Other methods of the invention include ways of using labeled dsRNA for RNAi.
    Type: Application
    Filed: June 12, 2002
    Publication date: December 9, 2004
    Inventors: Lance P. Ford, Mike Byrom, Brittan L. Pasloske
  • Patent number: 6825340
    Abstract: The present invention is a general method for inactivating or inhibiting ribonucleases. Ribonucleases are treated with a reducing agent and heat. RNA samples contaminated with ribonuclease may be treated with this method to protect them from degradation. The RNA may then be used directly in a variety of enzymatic reactions and molecular biology techniques. This method may also be applied to a variety of molecular biology reagents which may be contaminated with ribonuclease to protect an RNA from being degraded when incubated with the reagent.
    Type: Grant
    Filed: March 23, 2001
    Date of Patent: November 30, 2004
    Assignee: Ambion, Inc.
    Inventors: Brittan L. Pasloske, William Wu
  • Patent number: 6777210
    Abstract: The present invention is a general method for irreversibly inactivating ribonucleases. Ribonucleases are completely inactivated by treating them with a reducing agent and heat. RNA samples contaminated with ribonuclease may be treated with this method to protect them from degradation. The RNA may then be used directly in a variety of enzymatic reactions and molecular biology techniques. This method may also be applied to a variety of molecular biology reagents which may be contaminated with ribonuclease to protect an RNA from being degraded when incubated with the reagent.
    Type: Grant
    Filed: September 24, 1998
    Date of Patent: August 17, 2004
    Assignee: Ambion, Inc.
    Inventors: Brittan L. Pasloske, William Wu